Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Learn more:

• https://clinicaltrials.gov/study/NCT03448718
• News release

Manuscripts/Articles:

• D Doroshow, P O’Donnell, J Hoffman-Censits, S Gupta, U Vaishampayan, E Heath, P Garcia, Q Zhao, M Yu, M Milowsky, M Galsky. Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations: HCRN-GU15-262. DOI: 10.1200/PO.23.00095 JCO Precision Oncology. 2023 July 6. See abstract.